Original Publication Date: 11 February, 2014
Publication / Source: Journal of Comparative Effectiveness Research
Authors: Kitsada Wudhikarn & Brian K Link
Follicular lymphoma (FL) is the most common indolent non-Hodgkin’s lymphoma in northern America. FL is an incurable disease with relapsing–remitting courses requiring serial intermittent treatments. Duration of remission will often become progressively shorter and most patients will die from refractory disease or transformation to aggressive lymphoma. Given the incurable nature of FL, current goals of treatment are focused on improving symptoms and survival by a variety of available treatment options, while considering potential adverse events.